Development of protein expression and enzymatic activity potency assays for mRNA therapeutic development: A case study using GSDIII mRNA-LNP
Molecular Therapy Advances · 2026-12 · 34 (4) · 201872
DOI: 10.1016/j.omta.2026.201872 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Therapy Advances, 2026-12. Verfasst von Vibha Yadav und 4 weiteren Autor:innen. Beteiligte Einrichtung: Technical Development, Global CMC Development, Ultragenyx Pharmaceutical Inc., 7000 Shoreline Ct, South San Francisco, CA 94080, USA. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The emergence of mRNA vaccines and therapeutics demands robust analytical methods not only for biophysical characterization of their complex structures but also for assessing biological activity to reflect therapeutic function. This article describes the development of two complementary cell-based potency assays to analyze both protein expression and enzymatic activity of an mRNA-LNP (lipid nanoparticle) drug candidate for treating glycogen storage disease type III (GSDIII). An In-Cell Western (ICW) assay and a glycogen debranching enzyme (GDE) enzymatic activity assay were developed and optimized using HepG2 AGL KO cells, with human serum pre-treatment to enhance cellular uptake. Both methods demonstrated excellent assay performance, with accuracy between 80% and 120% and precision below 15% across their respective linear ranges. Additionally, the two assays also yielded comparable results when testing drug product (DP) samples with varying potency levels. Finally, potency assays detected decline in GDE protein expression and enzymatic activity in thermally stressed samples. These results correlate to mRNA degradation measured via capillary electrophoresis (CE), whereas the mRNA-LNP particle size and encapsulation efficiency remain unchanged. These findings demonstrate that cell-based potency assays are not only stability-indicating methods but also essential tools for analyzing the functional aspects of mRNA therapeutics, with broader applicability beyond this GSDIII case study.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Technical Development, Global CMC Development, Ultragenyx Pharmaceutical Inc., 7000 Shoreline Ct, South San Francisco, CA 94080, USA.
Zitieren
APA
Yadav, V., Prado, I., Haag, M., Bhambhani, A., & Meng, Z. (2026). Development of protein expression and enzymatic activity potency assays for mRNA therapeutic development: A case study using GSDIII mRNA-LNP. Molecular Therapy Advances, 34(4), 201872. https://doi.org/10.1016/j.omta.2026.201872
Vancouver
Yadav V, Prado I, Haag M, Bhambhani A, Meng Z. Development of protein expression and enzymatic activity potency assays for mRNA therapeutic development: A case study using GSDIII mRNA-LNP. Molecular Therapy Advances. 2026;34(4):201872. doi:10.1016/j.omta.2026.201872
BibTeX
@article{Yadav2026,
author = {Yadav, Vibha and Prado, Isaias and Haag, Molly and Bhambhani, Akhilesh and Meng, Zheng},
title = {Development of protein expression and enzymatic activity potency assays for mRNA therapeutic development: A case study using GSDIII mRNA-LNP},
journal = {Molecular Therapy Advances},
year = {2026},
volume = {34},
number = {4},
pages = {201872},
doi = {10.1016/j.omta.2026.201872}
}
EUVIMED